Biosimilars developer Coherus raises US$55 million investment

Biosimilars/News | Posted 06/06/2014 post-comment0 Post your comment

US-based biosimilars developer Coherus BioSciences (Coherus) announced on 19 May 2014 that it had raised investments of US$55 million. New investors KKR & Co LP, Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital.

24 AA011041

In October 2013, Coherus announced that its etanercept biosimilar, CHS-0214, had met the primary endpoint of clinical pharmacokinetic similarity to the originator biological Enbrel (etanercept) in a confirmatory clinical study in healthy subjects [1].

The investment will allow Coherus to proceed with its development plans, optimize the company’s partnering strategies and ‘deliver essential therapeutics to patients faster’, according to Denny Lanfear, President and CEO of Coherus. Mr Lanfear added that ‘since its founding four years ago, Coherus has made excellent progress on its goals of moving biosimilar biologic[al]s into phase III trials and onto the market’.

Coherus made an agreement with Daiichi Sankyo in May 2012 to develop and commercialize biosimilars of etanercept and rituximab in certain Asian countries including Japan [2]. Then in September 2013, Coherus made an exclusive collaboration agreement with Baxter International to develop and commercialize an etanercept biosimilar for Brazil, Canada, Europe and certain other markets [3].

Since Coherus was formed in 2010, the fledgling biotech company has raised over US$220 million from equity, licensing fees and milestones.

Related article

Biosimilars developments during 2013


1.  GaBI Online - Generics and Biosimilars Initiative. Etanercept biosimilar has comparable pharmacokinetics to Enbrel []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jin 6]. Available from:

2.  GaBI Online - Generics and Biosimilars Initiative. Daiichi Sankyo and Coherus Biosciences make biosimilars deal []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from:

3.  GaBI Online - Generics and Biosimilars Initiative. Baxter and Coherus to collaborate on biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Jun 6]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: Coherus

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010